Crinetics Pharmaceuticals (CRNX) Net Equity Issued and Repurchased (2017 - 2026)

Crinetics Pharmaceuticals' Net Equity Issued and Repurchased history runs 8 years deep, the most recent figure standing at $380.5 million for Q1 2026.

• In Q1 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $380.5 million; the TTM figure through Mar 2026 stood at $380.5 million (down 35.71% YoY), while the FY2024 annual figure was $985.0 million, up 166.54% from the prior year.
• Net Equity Issued and Repurchased for Q1 2026 stood at $380.5 million, down from $543.5 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $543.5 million in Q4 2024, with the low at -$13000.0 in Q3 2022.
• The 4-year median for Net Equity Issued and Repurchased is $188.6 million (2023), against an average of $215.6 million.
• The sharpest annual moves came in 2022 and 2023: Net Equity Issued and Repurchased slumped 100.09% in 2022, then soared 2530538.46% in 2023.
• Crinetics Pharmaceuticals' Net Equity Issued and Repurchased stood at -$13000.0 in 2022, then jumped by 225430.77% to $29.3 million in 2023, then soared by 1755.5% to $543.5 million in 2024, then dropped by 29.99% to $380.5 million in 2026.
• Business Quant data shows CRNX's Net Equity Issued and Repurchased at $380.5 million in Q1 2026, $543.5 million in Q4 2024, and $48.3 million in Q3 2024.